Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozone Treatment in Patients With Paresthesia Secondary to Chemotherapy-induced Peripheral Neuropathy
NCT06706544Phase 3Recruiting
- Start
- Feb 2025
- Primary completion
- Dec 2029
- Modality
- Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) and paresthesia comparing Ozone Group with Oxygen Group (Placebo) (2 arms). Primary endpoints: Change from baseline in numbness and tingling self-perceived by patients at 28 weeks and Change from Baseline in quality of life by the EQ-5D-5L at 28 weeks. Started Feb 2025; status: recruiting.
02
Drugs
medical ozonated water
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)paresthesia
Beyond the preview
Go deeper on NCT06706544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06706544.